NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Oryon Cell Therapies

Oryon Cell Therapies

Private
Belmont, MassachusettsHealthcare & Life Scienceshttps://oryoncelltherapies.com/

Last Round

Series A

Mar 23, 2026

Total Funding Raised

$42M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Oryon Cell Therapies is a biotechnology company that develops autologous cell therapies for neurodegenerative disorders, with an initial focus on Parkinson's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

Parkinson's diseasecell therapyiPSCsinduced pluripotent stem cellsregenerative medicineautologous therapystem cell therapyneuron replacementdopaminergic neuronsneurodegenerative disordersbiotechnologyclinical-stage biotechpersonalized medicineprecision medicineclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oryon Cell Therapies Comps

Public and private peers based on sector, stage, and business model.

Oryon Cell Therapies comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Oryon Cell Therapies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 23, 2026

Key People

Founding team and executive leadership

MD-PhD Nikola Kojic

Chief Innovation Officer & Co-Founder

Founding Team

Ron Cohen

CEO

Executive Team

Oryon Cell Therapies Investors

Notable investors and investment history

Oryon Cell Therapies investors
InvestorRounds
Byers CapitalSeries A
Neuro.VCSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    $21M round completed.

Oryon Cell Therapies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oryon Cell Therapies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oryon Cell Therapies's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelmont, Massachusetts
Employee Range3
Year Founded2020
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.